Fused Aromatic Ring Derivatives for Broad-Spectrum Mutant Kinase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents are inadequate in effectively inhibiting multiple protein tyrosine kinases, particularly those with mutations, leading to resistance and poor prognosis in various cancers and diseases.
Innovation Solution
A novel aromatic fused ring derivative with enhanced inhibitory activity and selectivity for wild-type and mutant RET, KIF5B-RET, CCDC6-RET, TrkA, TrkB, TrkC, FLT3, c-Kit, PDGFR, and VEGFR kinases, offering better pharmacodynamic and pharmacokinetic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents are used to inhibit protein tyrosine kinases, then some kinase activity is suppressed, but inhibitory effectiveness against multiple kinases particularly mutants is insufficient leading to resistance
Solution Approach 1:
The patent develops a compound of formula (I) that serves as a universal inhibitor for multiple protein tyrosine kinases including RET, TRK, FLT3, c-Kit, PDGFR, and VEGFR, both wild-type and mutant forms. The compound structure is designed to bind to the ATP-binding pocket of these kinases, providing broad-spectrum inhibition with a single agent, thus resolving the contradiction between targeting specificity and coverage versatility.
Solution Approach 2:
The patent optimizes the compound structure by modifying parameters such as the aromatic fused ring system, substituent groups (R1-R6), and molecular weight to enhance binding affinity and selectivity. Specific structural parameters are adjusted to improve inhibitory potency against mutant kinases while maintaining appropriate pharmacokinetic properties, thereby increasing reliability of inhibition across multiple targets.
2Reliability
If therapeutic agents are designed for high selectivity, then specificity for certain kinases is improved, but coverage of multiple kinase targets is reduced
Solution Approach 1:
The compound of formula (I) achieves multi-functionality by incorporating structural features that allow it to bind to conserved regions of multiple kinase families. The aromatic fused ring derivative structure with specific substituent patterns enables simultaneous interaction with RET, TRK, FLT3, c-Kit, PDGFR, and VEGFR kinases, providing both selectivity for the kinase family and versatility across individual targets.
Solution Approach 2:
The patent applies local quality by designing specific regions of the molecule with different functional characteristics. The core aromatic fused ring system provides the scaffold for kinase binding, while variable substituent groups (R1-R6) at different positions provide local interactions that tune selectivity and affinity for specific kinase targets, allowing the single compound to achieve both selectivity and broad coverage.
3Reliability
If compound structure is optimized for potency, then inhibitory activity is improved, but pharmacokinetic properties may be compromised
Solution Approach 1:
The patent systematically optimizes molecular parameters including molecular weight (250-500 Da), logP value (2-6), and hydrogen bond donors/acceptors to balance potency with pharmacokinetic properties. The compound structure is designed with appropriate molecular size and lipophilicity to ensure cell permeability and metabolic stability while maintaining high inhibitory activity against target kinases.
Solution Approach 2:
The patent introduces deuterium atoms at specific positions (R1-R6) to improve metabolic stability and pharmacokinetic properties locally without significantly affecting the overall binding affinity. This localized modification enhances the compound's half-life and oral bioavailability while preserving the potent inhibitory activity provided by the core structure.
Data Source
AI summary
Provided are a substituted fused aromatic ring derivative, a composition containing the compound, and a use thereof. The substituted fused aromatic ring derivative is a compound represented by formula (I) or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof. The compound and the composition can be used to treat various protein tyrosine kinase-mediated diseases or disorders.